📰 Paulk Audhya News
Paulk Audhya News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Paulk Audhya. Real-time updates on events, politics, business and more.
February 16, 2024
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 – ...
February 16, 2024
– Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--$KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule pro...
July 14, 2023
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the...
May 16, 2023
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 3,280,000 shares, a growth of 17.1% from the April 15th total of 2,800,000 shares. Currently, 14.0% of the shares of the company are sold […]
April 27, 2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today
April 1, 2023
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Rating) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 2,460,000 shares, a growth of 13.4% from the February 28th total of 2,170,000 shares. Based on an average daily volume of 351,700 shares, the days-to-cover ratio is […]
February 16, 2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today
February 7, 2023
Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan KalVista Pharmaceuticals, Inc. (NASDAQ:
February 7, 2023
07.02.2023 - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented three posters at the Western Society of ...
September 30, 2022
Data provides patient perspectives on optimal treatment outcomes and quality-of-life challenges for people living with HAE - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical